Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

License agreement extends access to culture-stable pooled hepatocyte cell models with increased longevity for use in DMPK and ADME studies

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • Preci, a biotechnology company advancing patient-derived cell models to bridge the gap between preclinical testing and clinical trials, and Biopredic International, (“Biopredic”), a biotechnology company specializing in the design and manufacture of human and animal in vitro assay systems, today announced a collaboration for the production of pooled suspension human hepatocytes.
  • This partnership strengthens our position in the human-derived assays market, providing our customers with access to high quality, reproducible assays, and we look forward to continuing to work with Biopredic to advance our translational models for use in drug metabolism and pharmacokinetics studies.
  • Accommodating both high- and low- clearance compounds, the stable and large-scale production of pooled suspension hepatocytes will increase throughput capacities for DMPK assays and reduce batch-to-batch deviation and assay costs, while the large availability of hepatocytes from multiple donors ensures diversity of CYP and Phase II enzymes.

Preci

Preci, a biotechnology company advancing patient-derived cell models to bridge the gap between preclinical testing and clinical trials, and Biopredic International, (“Biopredic”), a biotechnology company specializing in the design and manufacture of human and animal in vitro assay systems, today announced a collaboration for the production of pooled suspension human hepatocytes.

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

Human Hepatocytes

Pooled suspension human hepatocytes play a crucial role in assessing drug metabolism and hepatic clearance, providing a more representative understanding of human hepatic metabolism for predicting drug outcomes and assessing their impact on safety and efficacy. Despite this, the limited culture lifespan of pooled hepatocytes hinders long-term studies, potentially reducing metabolic competence with repeated use of the same batch.
Combining capabilities, Preci and Biopredic will provide pooled hepatocytes with an increased lifespan of over 12 hours, offering a single assay-based system to assess a broad range of drugs effectively and consistently. Accommodating both high- and low- clearance compounds, the stable and large-scale production of pooled suspension hepatocytes will increase throughput capacities for DMPK assays and reduce batch-to-batch deviation and assay costs, while the large availability of hepatocytes from multiple donors ensures diversity of CYP and Phase II enzymes. Under the license, Preci’s production capacity will reach 20,000 vials in 2024, greatly increasing global access to hepatocytes pooled and available to customers through Biopredic.

Anton Hanopolskyi, CEO, Preci, said:

“At Preci, we believe that increased diversity and availability of representative cell models will revolutionize the drug discovery landscape. This partnership strengthens our position in the human-derived assays market, providing our customers with access to high quality, reproducible assays, and we look forward to continuing to work with Biopredic to advance our translational models for use in drug metabolism and pharmacokinetics studies.”

Christophe Chesne, Founder, Biopredic International, commented:

“We are proud of Preci’s achievements made under our know-how license agreement. Biopredic now has first line access to many sources of primary hepatocytes suitable for further pooling. With the addition of Preci’s primary hepatocytes, our liver assay system portfolio comprises primary hepatocytes, the iconic HepaRG™ model and the newly launched HepaSH™, making Biopredic’s hepatic offering the most complete and advanced on the market.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company.  We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

By using this website you agree to accept Medical Device News Magazine Privacy Policy